Insider Buying: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Acquires $23,940.00 in Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel purchased 2,000 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were bought at an average price of $11.97 per share, with a total value of $23,940.00. Following the completion of the transaction, the chief executive officer now owns 5,543,702 shares of the company’s stock, valued at approximately $66,358,112.94. The trade was a 0.04 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link.

Snehal Patel also recently made the following trade(s):

• On Tuesday, January 7th, Snehal Patel acquired 1,800 shares of Greenwich LifeSciences stock. The stock was bought at an average price of $13.75 per share, for a total transaction of $24,750.00.
• On Monday, December 30th, Snehal Patel bought 3,200 shares of Greenwich LifeSciences stock. The stock was purchased at an average cost of $11.12 per share, for a total transaction of $35,584.00.

Greenwich LifeSciences Stock Down 3.3 %

GLSI opened at $13.35 on Thursday. Greenwich LifeSciences, Inc. has a 52 week low of $8.00 and a 52 week high of $21.44. The business has a fifty day simple moving average of $13.15 and a 200-day simple moving average of $14.13. The firm has a market cap of $175.49 million, a P/E ratio of -16.69 and a beta of 1.66.

Hedge Funds Weigh In On Greenwich LifeSciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. State Street Corp increased its stake in Greenwich LifeSciences by 4.4% during the third quarter. State Street Corp now owns 71,408 shares of the company’s stock worth $1,026,000 after purchasing an additional 3,005 shares during the period. Geode Capital Management LLC grew its holdings in shares of Greenwich LifeSciences by 4.6% in the third quarter. Geode Capital Management LLC now owns 133,550 shares of the company’s stock valued at $1,919,000 after purchasing an additional 5,861 shares in the last quarter. Barclays PLC increased its stake in Greenwich LifeSciences by 323.3% during the 3rd quarter. Barclays PLC now owns 8,560 shares of the company’s stock worth $123,000 after buying an additional 6,538 shares during the period. Rhumbline Advisers acquired a new stake in Greenwich LifeSciences during the 2nd quarter worth approximately $117,000. Finally, Bank of New York Mellon Corp purchased a new position in Greenwich LifeSciences in the 2nd quarter valued at approximately $264,000. 4.16% of the stock is currently owned by hedge funds and other institutional investors.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.